Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

26.95 -1.48 (-5.19%)
Streaming Delayed Price Updated: 10:30 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
The companies are chasing major innovations. 
Via The Motley Fool
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
The new drugs this company is developing could be worth a lot more than the present market value of its stock. 
Via The Motley Fool
(VKTX) - Analyzing Viking Therapeutics's Short Interest
Via Benzinga
Big Pharma Stocks: Who’s Leading The Race And Who’s Slipping?
Merck's wider drug moat and acquisition spree makes it a safer bet but VKTX can be the next LLY. 
Via Talk Markets
Unpacking the Latest Options Trading Trends in Viking Therapeutics
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $800 Today
Via Benzinga
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Viking Therapeutics's Options: A Look at What the Big Money is Thinking
Via Benzinga
Could Viking Therapeutics Become the Next Novo Nordisk?
Given this biotech's ascent, its odds of becoming a giant are better than most. 
Via The Motley Fool
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
There isn't much to suggest these businesses are actually vulnerable. 
Via The Motley Fool
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
3 Unstoppable Stocks to Buy in August
It's not hard to envision how all three of these stocks can deliver exceptional growth. 
Via The Motley Fool
Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now.
The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. 
Via The Motley Fool
What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.
Anti-obesity therapeutics are all the rage and for good reason. Investors seeking to profit should consider these weight loss stocks. 
Via InvestorPlace
8 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
Pfizer's debt load could inhibit the company's ability to take on acquisitions in the near term. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma
Both companies have a clear path to competing successfully in the market. 
Via The Motley Fool
3 Overlooked Stocks Poised for a Breakout Very Soon
Discover three overlooked breakout stocks with solid growth prospects, perfect for enhancing your investment portfolio. 
Via InvestorPlace
Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.
The Federal Reserve's fight against inflation may soon yield financial benefits. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.
One preliminary piece of evidence is sending its shares higher. 
Via The Motley Fool
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Should you get in on this stock now? 
Via The Motley Fool
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
Is Viking Therapeutics a Millionaire-Maker Stock?
The stock rose 120% in one trading session earlier this year on positive clinical trial news. 
Via The Motley Fool
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Small caps continued to lead, while the Nasdaq broke below key levels. 
Via Investor's Business Daily
Why Weight Loss Drug Developer Stocks Tumbled on Thursday
Companies like Novo Nordisk and Eli Lilly might soon have a determined competitor in their hottest product category. 
Via The Motley Fool
Novo Nordisk Shares Decline Amid Competitive Pressure
Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announcement from competitor Viking Therapeutics Inc. (NASDAQ:VKTX). 
Via Benzinga
Gold Down 2.5%; Northrop Grumman Posts Upbeat Earnings
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.